Evaluation of the Safety and Efficacy of the ReLARC Inserter During the Insertion Procedure of GYNEFIX Intrauterine Copper Bearing Contraceptive Device With a Follow-up of 3 Years.

Contraception Clinical Trial

— ReLARC  

Official title:

Evaluation of the Safety and Efficacy of the ReLARC Inserter During the Insertion Procedure of GYNEFIX Intrauterine Copper Bearing Contraceptive Device With a Follow-up of 3 Years.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05702281
• Other study ID #: REL-005
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2022
• Est. completion date: December 31, 2027

Study information

• Verified date: December 2023
• Source: University Hospital, Ghent
• Contact: Steven Weyers, MD
• Phone: 93327817
• Email: steven.weyers[@]uzgent.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Insertion under vision such as hysteroscopy allows the ability to visualize the uterus prior to insertion, to assess uterine compatibility and the assurance of proper device placement. ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe. This multicentre, open-label study will take place in the Women's Clinic of the Ghent University Hospital in Belgium (International Coordinating Centre) and in the University Hospital AOU Federico II of Naples in Italy. Primary aim: To evaluate the safety of the ReLARC® inserter during the insertion procedure of GyneFix® intrauterine copper bearing contraceptive devices by means of successful placement with adequate position during follow-up evaluations. Providing no complications develop, participants will remain in the study for 3 years. 120 women will be enrolled.

Description:

Insertion under vision such as hysteroscopy allows the ability to visualize the uterus prior to insertion, to assess uterine compatibility and the assurance of proper device placement. ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe. This multicentre, open-label study will take place in the Women's Clinic of the Ghent University Hospital in Belgium (International Coordinating Centre) and in the University Hospital AOU Federico II of Naples in Italy. Primary aim: To evaluate the safety of the ReLARC® inserter during the insertion procedure of GyneFix® intrauterine copper bearing contraceptive devices by means of successful placement with adequate position during follow-up evaluations. Providing no complications develop, participants will remain in the study for 3 years. 120 women will be enrolled. During the screeningsvisit the physician will introduce the trial. During the enrolment visit, the patient will sign the informed consent if she agrees to participate. During the insertion visit, the IUD will be placed, the correct location of the device will be determined, the ease of ReLARC insertion and hysteroscope insertion will be measured, the learning curve of the insertion will be registered and the pain score of the patient will be registered. After 4-8 weeks the first follow-up visit will take place. The location of the device will be determined and a satisfactory score of the patient about the IUD. During 3 years there's a yearly consultation with the gynaecologist where the location of the device and the satisfactory score about the IUD will be determined.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 48 Years

Eligibility

Inclusion Criteria:

• Generally healthy women, 18 - 48 years of age and not having a contraindication for hysteroscopy
• Be willing to come back for the follow-ups
• Be willing to refrain from having intercourse the first two weeks and using tampons and menstrual cups in the first 2 months, following insertion
• Sign a written informed consent
• Fundus thickness should be 11mm or more

Exclusion Criteria:

• T and Y shaped uterus
• U1, dysmorphic uterus (abnormal myometrium may result in bad device fixation)
• Complete septate U2b uterus
• Bicorporal U3-U6 uterus
• Injectables contraceptive use in the last year
• The presence of infection of the uterus, clinical cervicitis or vaginitis (infection should be ruled out)
• Intrauterine fibroids (intra-mural, intracavitary or submucosal)
• Cancer or other disease of the uterus
• Malignancy, or treatment for malignancy. Melanoma or any gynaecological cancer at any time excludes the subject
• Blood clotting disorders
• Intrauterine polyps
• Thrombophlebitis, thrombosis, or thromboembolic disorders
• Cerebrovascular accident, stroke, or transient ischemic attack
• Any cardiac, renal, or hepatic disease
• Subjects receiving corticosteroid therapy or immunosuppressive drugs
• Morbus Wilson
• AIDS

Related Conditions & MeSH terms

• Contraception

Intervention

Device:
• ReLARC
ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.

Locations

Country	Name	City	State
Belgium	University Hospital	Ghent

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Ghent	Federico II University

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positioning of the ReLARC IUD	To evaluate the position of the ReLARC® IUD to confirm the succesful placement of the IUD with the ReLARC inserter during every follow-up visit.	3 years
Secondary	Ease of insertion	1. The ease of the insertion (hysteroscope and ReLARC® device) by the following scale: Insertion went smoothly.; I had little trouble while inserting the device but experienced this as a not important delay in my surgical act.; Insertion was rather difficult.; Insertion was time consuming, difficult, and dangerous.; Insertion was not possible due to technical issues or medical reasons.	During Insertion visit
Secondary	Learning curve of ReLARC insertion	2. The learning curve of ReLARC® insertion, that starts after introducing the scope in the cervix and ends when the thread is cut and looped. This will be reported in minutes.	During Insertion visit
Secondary	Pain score	the participant's pain by a Visual Analogue Scale-VAS (1. no pain, 2. mild pain, 3. nasty pain, 4. severe pain, 5. unbearable pain) will be described.	During Insertion visit
Secondary	patient satisfactory	The patient satisfactory score will be determined at every follow-up visit (4-8 weeks after insertion; 1 year after insertion, 2 years after insertion and 3 years after insertion)	3 years after insertion
Secondary	Uterine cavity transverse diameter	the uterine cavity transverse diameter (UCTD) (before ReLARC® device insertion) will be described.	During insertion visit
Secondary	Expulsion rate	The number of expulsions of the IUD will be registered during the trial	7 years
Secondary	Removal rate	The number of early removal of the IUD will be registered during the trial	7 years
Secondary	Ease of removal	The ease of removal (Likert scale): 1. very easy, 2. easy, 3. neither easy nor difficult, 4. difficult, 5. very difficult	7 years
Secondary	Pain at removal	pain (VAS): 1. no pain, 2. mild pain, 3. nasty pain, 4. severe pain, 5. unbearable pain	7 years